Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
9c1pNfqBqRdmS7f4
